Toll-like receptor antagonist compounds and methods of use
Inventors
Candia, III, Albert Frederick • Beresis, Richard Thomas • Coffman, Robert L.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
Core Innovation
The disclosure describes a method of inhibiting cytokine production in a subject in need thereof by administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. The compound comprises a nitrogen-rich bicyclic heteroaromatic ring wherein two, three, or four of ring atoms A1 through A5 are nitrogen, linked to a nitrogen-containing ring with a basic carboxamide side chain. These compounds act as toll-like receptor antagonists to suppress immune responses and cytokine release associated with human TLR7, TLR8, and TLR9.
Structural embodiments encompass pyrazolo[3,4-d]pyridazine, indazole, pyrrolo[2,3-d]pyridazine, benzo[d]imidazole, and pyrazolopyridine scaffold families, particularly substituted piperidine-3- or -4-carboxamides, piperidinyl methanones, and formula (IIa-1b) through (IIa-1f) subfamilies. The targeted cytokines for inhibition explicitly comprise tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interferon-alpha. The compound scaffolds further include specific embodiments designated as Compounds 51 through 56.
Claims Coverage
The provided relevant claims identify one independent claim directed to a method of inhibiting cytokine production, presenting three inventive features.
Inhibiting cytokine production
The claim defines a method of inhibiting the production of a cytokine in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
Formula (I) compound framework
The compound possesses a formula (I) structure wherein two, three, or four of ring atoms A1, A2, A3, A4, and A5 are nitrogen, alongside defined substituents R1 through R10.
Linker and ring-forming options
The claim specifies linker U as a bond or methylene optionally substituted by R10, and linker V as a bond or C1-C2 alkylene optionally substituted by R10, alongside defined substituent options to form alkylene, heterocyclyl, or heteroaryl rings.
The independent claim covers a method of inhibiting cytokine production through the administration of a therapeutically effective amount of a defined formula (I) compound, salt, or solvate, encompassing specified heterocyclic cores, linkers, and substituent selections.
Stated Advantages
The compounds are described as suppressing immune responses and inhibiting inflammatory cytokine responses, particularly TLR8- and/or TLR9-dependent responses.
Documented Applications
Inhibiting cytokine production in a subject in need thereof, wherein the specified target cytokines include tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interferon-alpha.
Inhibiting TLR-dependent responses to treat immune disorders, autoimmune and inflammatory disorders, infections, pathogen stimulation, and selected cancers including TLR-dependent cancers.
Interested in licensing this patent?